Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.
ObsEva SA is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, specializing in the development and commercialization of novel therapies to enhance women's reproductive and pregnancy health. Founded in 2012, ObsEva is dedicated to addressing unmet needs in reproductive medicine by focusing on innovative treatments that aim to improve fertility outcomes and manage preterm labor.
Currently, ObsEva is involved in several key projects, including their lead product linzagolix, an oral GnRH antagonist designed to treat uterine fibroids and endometriosis. This medication aims to offer significant benefits over existing treatments by providing symptom relief with fewer side effects.
ObsEva's approach is underscored by a robust pipeline and strategic partnerships with leading healthcare organizations. Financially, the company continues to navigate its path with a focus on securing funding to propel its clinical trials and regulatory submissions. Recently, ObsEva has made significant strides with positive results from their Phase 3 trials for linzagolix, putting them on track for potential market approval.
ObsEva's commitment to innovation and patient health is reflected through its continuous efforts in research and development, making significant progress in areas with high medical needs. The company's forward-looking strategy is built on scientific rigor, collaborative partnerships, and a deep understanding of women's health issues.
For more information, please contact:
General inquiries: contact@obseva.ch
Investor relations: IR@obseva.ch
ObsEva SA
Chemin des Aulx 12,
1228 Plan-les-Ouates,
Switzerland
ObsEva SA (NASDAQ: OBSV) announced two significant peer-reviewed publications on nolasiban, an oxytocin receptor antagonist aimed at enhancing live birth rates post-embryo transfer in IVF. The first study reported a 5% absolute increase in ongoing pregnancy rates across three trials involving over 1,800 patients. The second study highlighted nolasiban's effects on uterine contractions and mRNA expression, indicating its potential to improve ART outcomes. These findings may pave the way for further clinical developments of nolasiban in reproductive health.
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focusing on women's reproductive health, has scheduled corporate updates for the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 8 a.m. EST, and the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 9 a.m. EST. Both presentations will be webcasted, with archived access available on ObsEva's website. ObsEva is developing therapies for conditions like endometriosis and uterine fibroids.
ObsEva and Organon have announced a partnership to develop ebopiprant (OBE022), a potential treatment for preterm labor, addressing a significant unmet medical need. The agreement grants Organon the global rights to develop and commercialize ebopiprant, with ObsEva set to receive up to $500 million, consisting of upfront and milestone payments along with tiered royalties. Ebopiprant has shown promise in clinical trials, reducing preterm delivery rates in singleton pregnancies by 55% compared to standard care.
Organon (NYSE: OGN) and ObsEva (NASDAQ: OBSV) have announced a licensing agreement for ebopiprant (OBE022), an investigational drug aimed at treating preterm labor. This agreement allows Organon exclusive global development and commercialization rights for ebopiprant, which could fill a critical gap in acute preterm labor treatment in the U.S. ObsEva will receive up to $500 million, including $25 million at signing, and tiered royalties on sales. The drug shows promise based on Phase 2a trial results, which indicated a significant reduction in preterm deliveries.
ObsEva has announced the presentation of clinical data from the PROLONG Phase 2a study of ebopiprant (OBE022), an oral prostaglandin F2alpha antagonist for spontaneous preterm labor. This data will be showcased at the Society for Reproductive Investigation’s 68th Annual Meeting on July 6-9, 2021. Key presentations include a randomized, placebo-controlled trial and discussions on the pharmaceutical landscape in preterm labor treatment. The sessions will be led by Elizabeth Garner, M.D., and will occur on July 7 and 8, 2021.
ObsEva SA (NASDAQ: OBSV) revealed promising clinical data at the ESHRE Annual Meeting, showcasing Yselty®'s efficacy for treating severe adenomyosis and uterine fibroids. The pilot study indicated a significant reduction in uterine volume by 57% after 12 weeks. In two Phase 3 studies, Yselty demonstrated effectiveness in reducing heavy menstrual bleeding, with improvements in pain and quality of life maintained for 52 weeks. Additionally, nolasiban showed significant effects on uterine contractility in IVF patients. These results highlight Yselty's potential in reproductive health.
ObsEva SA (NASDAQ: OBSV) announced the upcoming presentation of data from its clinical programs at the ESHRE Virtual 37th Annual Meeting from June 26 to July 1, 2021. Key presentations include:
- Long-Term Efficacy of Linzagolix for treating heavy menstrual bleeding due to uterine fibroids, presented orally on June 29, 2021.
- Initial Results of Linzagolix for severe adenomyosis in an ePoster format.
- Nolasiban's effects on uterine contractility in IVF patients, also in ePoster format.
Details are available on ObsEva's website.
ObsEva SA (NASDAQ: OBSV) presented positive clinical data from the PROLONG Phase 2a study of ebopiprant for treating spontaneous preterm labor. Results indicate that ebopiprant, when combined with atosiban, reduced delivery within 48 hours by over 50% compared to atosiban alone. The company plans to initiate a Phase 2b/3 adaptive study in Q4 2021, which could support accelerated registration in Europe. Ebopiprant offers a unique mechanism for preventing preterm birth, indicating significant potential in women's health therapeutics.
ObsEva SA (NASDAQ: OBSV) has announced that data from the PROLONG Phase 2a proof-of-concept study for ebopiprant will be presented at the Royal College of Obstetricians and Gynaecologists (RCOG) Virtual World Congress 2021 from June 9-12. Ebopiprant, a selective prostaglandin F2α receptor antagonist, aims to treat spontaneous preterm labor. The oral presentation is scheduled for June 12, 2021, at 8:10 a.m. GMT, by Dr. Ben Mol from Monash Medical Centre.
ObsEva SA (NASDAQ: OBSV/SIX: OBSN) announced that shareholders approved all Board proposals at its 2021 Annual General Meeting on May 28, 2021. Key approvals included the Annual Report and Financial Statements for 2020, discharge for the Board members, and various elections for the Board and committees. Additionally, shareholders approved increases in Authorized and Conditional Share Capital and changes to the Equity Incentive Plan. These decisions support ObsEva's commitment to advancing women's reproductive health.
FAQ
What is ObsEva SA's core business?
Where is ObsEva SA headquartered?
What is linzagolix?
How can I contact ObsEva for general information?
How can investors get in touch with ObsEva?
What are some recent achievements of ObsEva?
Does ObsEva have any strategic partnerships?
What is the focus of ObsEva's research and development?
How does linzagolix differ from existing treatments?
What is ObsEva's commitment to women's health?
